According to an ongoing phase 1/2a trial of RGX-314 gene therapy for wet age-related macular degeneration, six participants who have reached 2-year follow-up have experienced long-term, durable treatment effects and improvements in vision.
The trial drug, a potential one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions treated with anti-VEGF, has been well-tolerated at all dose levels through five cohorts of participants, according to a press release from Regenxbio.
“I’m pleased to say the data continues to support what we’ve previously
Uncategorized